metaShape Pharma

MetaShape Pharma is a Swiss biotechnology company focused on developing first-in-class metabolic therapies to treat obesity and age-related diseases. The company's lead program, MS 001 (ulodesine hemiglutarate), is an oral small-molecule inhibitor of purine nucleoside phosphorylase (PNP) designed to restore NAD+ levels and reprogram fat metabolism. By activating energy-consuming processes in white adipose tissue, MS 001 aims to enhance fat-selective weight loss and preserve muscle mass, particularly when used as a co-therapy with GLP-1 receptor agonists. Founded in 2023 and based in Basel, MetaShape is targeting a range of conditions including metabolic dysfunction, cardiometabolic diseases, and neurodegeneration. The company leverages its expertise in nucleoside metabolism and bioenergetics to address the root causes of metabolic decline associated with aging.